{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:09:22Z","timestamp":1791259762194,"version":"4.1.0"},"reference-count":61,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Lassa fever (LF) is caused by a viral pathogen with pandemic potential. LF vaccines have the potential to prevent significant disease in individuals at risk of infection, but no such vaccine has been licensed or authorised for use thus far. We conducted a scoping review to identify and compare registered phase 1, 2 or 3 clinical trials of LF vaccine candidates, and appraise the current trajectory of LF vaccine development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We systematically searched 24 trial registries, PubMed, relevant conference abstracts and additional grey literature sources up to 27 October 2022. After extracting key details about each vaccine candidate and each eligible trial, we qualitatively synthesised the evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that four LF vaccine candidates (INO\u20104500, MV\u2010LASV, rVSV\u2206G\u2010LASV\u2010GPC, and EBS\u2010LASV) have entered the clinical stage of assessment. Five phase 1 trials (all focused on healthy adults) and one phase 2 trial (involving a broader age group from 18\u2009months to 70\u2009years) evaluating one of these vaccines have been registered to date. Here, we describe the characteristics of each vaccine candidate and trial and compare them to WHO's target product profile for Lassa vaccines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tmi.13876","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:14:54Z","timestamp":1682396094000},"page":"420-431","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Lassa fever vaccine candidates: A scoping review of vaccine clinical trials"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-0094","authenticated-orcid":false,"given":"Giorgia","family":"Sulis","sequence":"first","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine University of Ottawa  Ottawa Canada"},{"name":"Clinical Epidemiology Program Ottawa Hospital Research Institute  Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Peebles","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences McGill University  Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-6353","authenticated-orcid":false,"given":"Nicole E.","family":"Basta","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences McGill University  Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.3.445"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1008811"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1212.060812"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-56029-3_4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S147276"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2505.181247"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27219"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6648.584"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7426.1271"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/019459989210600303"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz512"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.08.021"},{"issue":"1","key":"e_1_2_6_14_1","first-page":"1","article-title":"Lassa fever in west African sub\u2010region: an overview","volume":"44","author":"Ogbu O","year":"2007","journal-title":"J Vector Borne Dis"},{"key":"e_1_2_6_15_1","volume-title":"An R&D blueprint for action to prevent epidemics: plan of action","author":"World Health Organization (WHO)","year":"2016"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxz012"},{"key":"e_1_2_6_17_1","unstructured":"CEPI: Priority diseases: Coalition for Epidemic Preparedness Innovations (CEPI).2022Available from:https:\/\/cepi.net\/research_dev\/priority-diseases\/"},{"issue":"1","key":"e_1_2_6_18_1","first-page":"30","article-title":"The impact of COVID\u201019 on communicable and non\u2010communicable diseases in Africa: a narrative review","volume":"30","author":"Formenti B","year":"2022","journal-title":"Infez Med"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-005988"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07972"},{"key":"e_1_2_6_21_1","volume-title":"Global community comes together in support of 100\u2009days Mission and pledges over $1.5 billion for CEPI's pandemic\u2010busting plan [press release]","year":"2022"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.08.002"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25910-y"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33112-3"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)90659-7"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.15.6992-7004.2000"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804498"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00789-8"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30486-4"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101668"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0049-5"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2019.07.006"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.139"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2019.03.008"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24702"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2011.209"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-017-1486-3"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00048-X"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37050-6"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00093-4"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1649532"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03276-13"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020183"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003736"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111094"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131958"},{"key":"e_1_2_6_47_1","unstructured":"Safety tolerability and immunogenicity of INO\u20104500 in healthy volunteers (Identifier: NCT03805984): US National Library of medicine.2019Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03805984?cond=lassa&draw=2&rank=8"},{"key":"e_1_2_6_48_1","unstructured":"Dose\u2010ranging study: safety tolerability and Immunogenicity of INO\u20104500 in healthy volunteers in Ghana (Identifier: NCT04093076). US National Library of Medicine.2019Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04093076?cond=lassa&draw=2&rank=7"},{"key":"e_1_2_6_49_1","unstructured":"MarreroI.INO 4500 a DNA based LASV vaccine induces robust T cell responses and long\u2010term memory antigen\u2010specific T cells. International Vaccines Congress (IVC); Orlando USA. (hybrid event)2021."},{"key":"e_1_2_6_50_1","unstructured":"Press release: INOVIO completes enrollment of phase 1B clinical trial for its DNA vaccine candidate against lassa fever. Inovio Pharmaceuticals Inc. INO\u20104500 in West Africa [October 26 2021] [press release]2021."},{"key":"e_1_2_6_51_1","unstructured":"A trial to evaluate the optimal dose of MV\u2010LASV (V182\u2010001) (Identifier: NCT04055454): US National Library of Medicine. ClinicalTrials.gov.2019Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04055454?term=NCT04055454&draw=1&rank=1"},{"key":"e_1_2_6_52_1","volume-title":"10th EDCTP forum","author":"Gupta S","year":"2021"},{"key":"e_1_2_6_53_1","unstructured":"A clinical trial to evaluate the safety and immunogenicity of rVSV\u2206G\u2010LASV\u2010GPC vaccine in adults in good general heath (Identifier: NCT04794218): US National Library of Medicine. ClinicalTrials.gov.2021Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04794218?cond=lassa&draw=2&rank=9"},{"key":"e_1_2_6_54_1","unstructured":"A phase 1 randomized double\u2010blinded placebo\u2010controlled dose\u2010escalation clinical trial to evaluate the safety and immunogenicity of rVSV\u2206G\u2010LASV\u2010GPC vaccine in adults in good general health (Identifier: PACTR202106625781067): Pan African Clinical Trial Registry.2021Available from:https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=15920"},{"key":"e_1_2_6_55_1","unstructured":"Pan African Clinical Trial Registry.A phase 2 randomized double\u2010blinded placebo\u2010controlled clinical Trial to evaluate the safety tolerability and immunogenicity of rVSV\u2206G\u2010LASV\u2010GPC vaccine in adults and children residing in West Africa (Identifier: PACTR202210840719552) 2022. Available from:https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=23666"},{"key":"e_1_2_6_56_1","unstructured":"A study to assess a new Lassa virus vaccine in healthy volunteers (Identifier: PACTR202108781239363): Pan African Clinical Trial Registry.2021Available from:https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=14618"},{"key":"e_1_2_6_57_1","volume-title":"WHO target product profile for Lassa virus vaccine","author":"World Health Organization (WHO)","year":"2017"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.20.273375"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2018.08.033"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00481-y"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2005630"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.003"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T20:29:55Z","timestamp":1692563395000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.13876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/tmi.13876"],"URL":"https:\/\/doi.org\/10.1111\/tmi.13876","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"2023-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}